- Home
- PEW vs KZIA Comparison
PEW vs KZIA Comparison
Compare PEW & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEW | KZIA |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.9M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | PEW | KZIA |
|---|---|---|
| Price | $2.46 | $13.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.75 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 351.7K | 192.6K |
| Earning Date | 05-13-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.25 | N/A |
| Revenue Next Year | $7.96 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.39 | $4.86 |
| 52 Week High | $10.04 | $17.40 |
Technical Indicators
Market Signals| Indicator | PEW | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 58.83 |
| Support Level | N/A | $5.62 |
| Resistance Level | $3.33 | $14.57 |
| Average True Range (ATR) | 0.13 | 1.10 |
| MACD | -0.01 | 0.22 |
| Stochastic Oscillator | 19.65 | 74.66 |
Price Performance
Historical ComparisonAbout PEW GrabAGun Digital Holdings Inc.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.